Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803075 | 0.83 | PTGS2 (0.52) | CA2PTGS2HTTNPSR1TUBB1 | |
| SCHEMBL14764254 | 0.82 | KDM4E (0.48) | CA2LMNAKMT2AGAAKDM4E | |
| SCHEMBL14764203 | 0.82 | MAPT (0.42) | HTTNPSR1LMNASMN1; SMN2GAA | |
| SCHEMBL11950523 | 0.81 | CA2 (0.48) | CA2PTGS2HTTNPSR1TUBB1 | |
| SCHEMBL31428 | 0.80 | CA2 (0.71) | CA2PTGS2HTTLMNAKMT2A | |
| SCHEMBL31275634 | 0.80 | CA2 (0.71) | CA2PTGS2HTTLMNAKMT2A | |
| SCHEMBL3691694 | 0.79 | HTR7 (0.58) | CA2LMNAKMT2AALDH1A1 | |
| SCHEMBL8940769 | 0.78 | HTR7 (0.53) | CA2PTGS2HTTTUBB1LMNA | |
| Water SCHEMBL8587595 | 0.78 | CA2 (0.68) | CA2PTGS2HTTLMNAKMT2A | |
| Ammonia Solution, Strong SCHEMBL266403 | 0.78 | CA2 (0.68) | CA2PTGS2HTTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190085007-A1 | 4-methylcatechol Derivatives and Uses Thereof | Thanares GmbH (DE) | 2019-03-21 | — | — | US | claimed |
| US-20160347782-A1 | 4-methylcatechol Derivatives and Uses Thereof | Thanares GmbH (DE) | 2016-12-01 | — | — | US | claimed |
| WO-2013034119-A1 | 4-METHYLCATECHOL DERIVATIVES UND USE THEREOF | Thanares GmbH (DE) | 2013-03-14 | — | — | WO | claimed |
| US-20190085007-A1 | 4-methylcatechol Derivatives and Uses Thereof | Thanares GmbH (DE) | 2019-03-21 | — | — | US | disclosed |
| US-20160347782-A1 | 4-methylcatechol Derivatives and Uses Thereof | Thanares GmbH (DE) | 2016-12-01 | — | — | US | disclosed |
| WO-2013034119-A1 | 4-METHYLCATECHOL DERIVATIVES UND USE THEREOF | Thanares GmbH (DE) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085007-A1 | 4-methylcatechol Derivatives and Uses Thereof | ST3GAL3, GALE, DPP4 | CA2 1669/4885PTGS2 1756/4885HTT 2102/4885 |
| US-20160347782-A1 | 4-methylcatechol Derivatives and Uses Thereof | ST3GAL3, GALE, DPP4 | CA2 1669/4885PTGS2 1756/4885HTT 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.